B-cell and T-cell lymphomas can look identical on a scan and produce the same symptoms, but they arise from different types of immune cells and require different treatment regimens.
CHOP Without Rituximab — Why R Is Sometimes Left Out
CHOP is a four-drug chemotherapy regimen. When rituximab — the R — is not included, it is usually because your lymphoma does not express CD20, the protein rituximab needs to work. Cost is a second factor, and your oncologist will name both openly.
- Four drugs, not five — CHOP stands for cyclophosphamide, doxorubicin, vincristine and prednisolone. Rituximab is a fifth agent added only when the tumour expresses CD20.
- CD20 testing decides first — Your biopsy is tested for CD20 expression before any treatment begins. A negative result means rituximab has no target and is not given.
- T-cell lymphomas never get rituximab — T-cell lymphomas do not express CD20 at all. For these, CHOP without rituximab is the correct regimen — not a reduced one.
- Cost is named openly — Rituximab adds significant cost. Biosimilars have reduced this, but your oncologist will discuss the clinical and financial picture together.
Medically reviewed by Dr. Naresh Gundu, Medical Oncologist, MBBS (Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar) · DNB Internal Medicine (Sir Gangaram Hospital, New Delhi) · DM Medical Oncology (AIIMS) · Last reviewed September 2026
CHOP is a four-drug regimen — cyclophosphamide, doxorubicin, vincristine and prednisolone. The R in R-CHOP is rituximab, an antibody added when the lymphoma expresses CD20. When CD20 is absent — as in T-cell lymphomas — rituximab has no target and is not given. Cost is a second factor your team will discuss directly.
What does each letter in CHOP stand for?
CHOP is an acronym for four drugs: cyclophosphamide, doxorubicin (also called hydroxydaunorubicin, which gives the H), vincristine (sold as Oncovin, which gives the O) and prednisolone or prednisone.
Each drug works through a different mechanism, and giving them together makes the combination harder for lymphoma cells to resist than any single agent alone.
Rituximab is a monoclonal antibody that can be added as a fifth agent when the tumour expresses CD20. When it is added, the regimen becomes R-CHOP. When it is not, the regimen is CHOP.
When is rituximab left out of CHOP?
The most common reason is a negative CD20 result. Rituximab works by binding to CD20, a protein on the surface of certain lymphoma cells. If CD20 is absent, the antibody has nothing to attach to and would add side effects without adding benefit.
T-cell lymphomas never express CD20. For these, CHOP without rituximab is the correct regimen — not a lesser version, but the one that matches the biology.
Cost is a second, legitimate factor. Rituximab adds significant expense even where biosimilars are available. Your oncologist will tell you what the CD20 result showed and, if rituximab is clinically indicated, what the cost options are.
Who is CHOP chemotherapy not suitable for?
CHOP is not used in the following situations, and eligibility is decided by an oncologist on the individual case:
- Patients whose lymphoma does not match CHOP's scope — CHOP is a regimen for certain lymphomas, not solid tumours or other blood cancers.
- Patients with significantly reduced heart function — doxorubicin, the H in CHOP, can affect the heart muscle, and poor cardiac function may make this drug unsuitable.
- Patients with severely impaired kidney or liver function — several CHOP drugs depend on these organs for clearance, and significant impairment affects tolerability.
- Patients whose overall fitness does not allow intensive chemotherapy — age, performance status and other medical conditions all affect whether the full regimen is appropriate.
- CD20-positive cases where rituximab is contraindicated — a severe prior reaction to rituximab means the R may be omitted even when the tumour is CD20-positive.
Your oncologist decides suitability on your individual test results, fitness and diagnosis.
How does the team decide which regimen you get?
Biopsy
A tissue sample is taken from the affected lymph node or tumour site.
Immunohistochemistry
The laboratory stains the sample to look for CD20 expression on the tumour cells. The test also confirms whether the lymphoma is B-cell or T-cell in origin.
Pathology report issued
The report names the lymphoma type and records the CD20 result — positive, negative or equivocal.
Oncologist reviews the full picture
Your oncologist reads the pathology report alongside your staging scans, blood tests, heart function and overall fitness before deciding on the regimen.
Regimen named on the treatment plan
The plan names CHOP or R-CHOP and states why. You should be told the CD20 result and the reasoning before your first cycle begins.
What does CHOP without rituximab look like in practice?
The four drugs are given in cycles, with a rest period between each, over a course that your oncologist decides based on your disease and how you respond.
The intravenous drugs are typically given on day one of each cycle as a day-care infusion. Prednisolone is taken as tablets for the first several days of the cycle.
Without rituximab, the infusion session is shorter — there is no lengthy antibody preparation or pre-medication at the start of the day.
Monitoring during and after treatment — blood counts, organ function and response imaging — is the same whether your regimen is CHOP or R-CHOP.
Did you know?
The distinction is invisible without a biopsy. A scan alone cannot tell your oncologist whether rituximab belongs in your treatment plan.
Source: WHO Classification of Haematolymphoid Tumours, 5th edition
Explore 82 more How Chemotherapy Is Given: Regimens, Cycles & Infusion Days topics
Chemotherapy Regimens by Name
- 7+3 and Induction Regimens for Acute Leukaemia
- ABVD Regimen for Hodgkin Lymphoma
- AC and EC Regimens
- AC-T Regimen for Breast Cancer
- BEP Regimen for Testicular and Germ Cell Cancer
- CAPOX and XELOX Regimens
- CHOP Without Rituximab
- Carboplatin-Paclitaxel Regimen
- Cervical Cancer Chemotherapy and Chemoradiation Regimens
- Chemotherapy Regimens: What the Acronyms Mean
- Cisplatin-Pemetrexed and Platinum-Pemetrexed
- Comparing Two Regimens: How the Choice Is Made
- DCF and FLOT Regimens for Stomach Cancer
- Doxorubicin-Ifosfamide and Sarcoma Regimens
- EP and Carboplatin-Etoposide for Small Cell Lung Cancer
- FEC and CMF Regimens
- FOLFIRI Regimen
- FOLFIRINOX and Modified FOLFIRINOX
- FOLFOX Regimen for Colorectal Cancer
- GemCis and MVAC for Bladder Cancer
- Gemcitabine-Nab-Paclitaxel for Pancreatic Cancer
- R-CHOP Regimen for Lymphoma
- Salvage Lymphoma Regimens: ICE, DHAP and ESHAP
- TC Regimen (Docetaxel and Cyclophosphamide)
- TPF and Cisplatin Regimens for Head and Neck Cancer
- VRd, VCd and Myeloma Regimens
- Weekly Cisplatin With Radiation (Chemoradiation)
- Which Regimen Is Used for Which Cancer?
Cycle Delays, Dose Reductions & Changes
- Does a Delay Mean the Cancer Is Growing?
- Does a Reduced Dose Still Work?
- Growth Factor Support to Keep the Schedule
- How Many Delays Are Too Many?
- Infection Delaying a Cycle
- My Counts Were Too Low and the Cycle Was Postponed
- Organ Function Problems Delaying a Cycle
- Stopping Early: What Happens If You Do Not Complete the Course?
- Transfusion During Chemotherapy
- What If I Cannot Tolerate the Treatment?
- What Is a Dose Reduction and Why Was Mine Reduced?
- What to Ask If Your Plan Changes
- Why Chemotherapy Gets Delayed or Reduced
- Why Was My Regimen Switched?
HUB — Chemotherapy Regimens
HUB — Cycles, Schedules and What Happens on Infusion Day
How Chemotherapy Is Given
- Can Chemotherapy Be Given at Home?
- Can Chemotherapy Be Given at a Local Hospital?
- Continuous Infusion Chemotherapy and Portable Pumps
- Day Care vs Admission for Chemotherapy
- How Is Chemotherapy Given? All the Routes Explained
- How Long Does Each Chemotherapy Session Take?
- Intra-Arterial and Regional Chemotherapy
- Intraperitoneal Chemotherapy
- Intrathecal Chemotherapy: Into the Spinal Fluid
- Intravenous Chemotherapy: What the Drip Involves
- Intravesical Chemotherapy for the Bladder
- Is Oral Chemotherapy Weaker Than Injections?
- Oral Chemotherapy: Tablets Instead of a Drip
- Subcutaneous and Intramuscular Chemotherapy
- Topical Chemotherapy Creams
- What Safety Checks Happen Before Each Dose?
- Who Actually Gives Your Chemotherapy?
- Why Does the Route Sometimes Change During Treatment?
Regimens, Cycles & Schedules
- A Printable Chemotherapy Cycle Calendar
- Adding or Removing Cycles Mid-Course
- Blood Tests Before Every Cycle: What They Check
- Day 1, Day 8, Day 15: What the Day Numbers Mean
- Does Delaying a Cycle Reduce the Benefit?
- How Many Cycles Before the First Assessment?
- How the Dose Is Calculated for You
- Keeping a Chemotherapy Symptom Diary
- Planning Your Life Around Chemotherapy Cycles
- Rescheduling or Missing a Chemotherapy Appointment
- Weekly, Two-Weekly and Three-Weekly Schedules
- What Happens Between Cycles?
- What Happens at the Last Cycle?
- What Is Dose Intensity?
- What Is a Chemotherapy Cycle?
- What Is the Nadir and Why Does It Matter?
- Which Days of the Cycle Will I Feel Worst?
- Why Was My Cycle Postponed?
The Infusion Day
Your First Cycle
All How Chemotherapy Is Given: Regimens, Cycles & Infusion Days →
Frequently asked questions
Does CHOP without rituximab mean my treatment is weaker?
No. For lymphomas that do not express CD20, CHOP is the appropriate regimen — not a reduced one. Rituximab without a CD20 target would add infusion reactions and other side effects without contributing to treatment. The regimen you receive is chosen because it matches your tumour biology, not because something has been withheld.
Can rituximab be added partway through if things change?
CD20 status generally does not change during treatment, so the decision made at diagnosis usually stands for the whole course. In some situations — a revised diagnosis after more detailed pathology, or a reassessment — your oncologist may revisit the question. If you want to understand the reasoning, ask for the CD20 result in writing and ask what would change the decision.
What side effects should I expect from CHOP without rituximab?
The side effects of the four CHOP drugs still apply. These can include a fall in blood counts, increased risk of infection, hair loss, nausea, mouth sores, and nerve effects from vincristine such as tingling in the hands or feet. Without rituximab, you avoid the infusion reactions associated with the antibody — chills, fever and occasionally more serious reactions during the infusion itself. Your team will tell you which effects to watch for and when to call.
If my CD20 result is positive, can rituximab still be left out?
Yes, in some circumstances. A severe allergy or prior reaction to rituximab may mean it cannot safely be given. Certain other medical conditions may also affect the decision. These are individual clinical judgements made by your oncologist. If you have a CD20-positive lymphoma and rituximab is being omitted, ask your oncologist to explain the specific reason for your case.
What is a biosimilar rituximab and does it work the same way?
A biosimilar is a version of rituximab produced by a different manufacturer after the original patent expired. To be approved, it must demonstrate equivalent clinical effect to the original product. Biosimilars have significantly reduced the cost of rituximab in India and are used widely. If cost is a concern for your family, ask your oncologist whether a biosimilar version is available and appropriate for your regimen.
Will I know which regimen I am getting before treatment starts?
Yes. The regimen should be named explicitly in your treatment plan before your first cycle begins. Ask your oncologist to confirm whether you are receiving CHOP or R-CHOP, what your CD20 result showed, and the reason for the choice. Writing the answers down helps — these conversations are hard to recall accurately afterwards, and the information is yours to keep and refer back to.
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Chemotherapy Topics
Browse our complete chemotherapy guide — 1133 pages on side effects, medicines, cost, daily life and care in Hyderabad. Tap any topic to read more.